Alzheimer’s scientists critique Cassava Sciences’ study results — overblown, inappropriate, uninterpretable

Independent researchers are expressing doubts about the purported benefits of an experimental treatment for Alzheimer’s from Cassava Sciences.

The company said Thursday that a preliminary analysis of a small clinical trial showed its drug, called simufilam, improved the cognition of patients with Alzheimer’s disease — a benefit that no other treatment for Alzheimer’s has ever shown.

Asked by STAT to examine the simufilam data, Alzheimer’ scientists not involved in Cassava’s study said the cognitive benefit claim was exaggerated and not supported by the design of the clinical trial.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In